SEQ-400 is a vaccine against urinary tract infections (UTIs) which is under development for potential medical use.[1][2][3] It is a vaccine against the Escherichia coli FimH adhesin protein, which is essential for bacterial infection.[3] The vaccine is being developed by Sequoia Sciences.[1][2] As of September 2023, it is in phase 2 clinical trials.[1][2] SEQ-400 is being developed for potential approval and use in the United States.[1]

See also

References

  1. ^ a b c d e "SEQ 400". AdisInsight. 15 September 2023. Retrieved 26 February 2025.
  2. ^ a b c "Delving into the Latest Updates on SEQ-400 with Synapse". Synapse. 23 January 2025. Retrieved 26 February 2025.
  3. ^ a b "Why Do Urinary Tract Infections (UTI) Recur?". ASM.org. 3 May 2024. Retrieved 26 February 2025.


Allikas: https://en.wikipedia.org/wiki/SEQ-400
No tags for this post.